An Open-label, Dose Escalation Phase I Study of the Safety and Tolerability of BIBF 1120 in Combination With Carboplatin and Pegylated Liposomal Doxorubicin (PLD) in Japanese Patients With a First, Second or Third Platinum-sensitive Relapse of Advanced Epithelial Ovarian Cancer, Fallopian Tube or Primary Peritoneal Cancer.
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
To determine Maximum tolerated dose of BIBF 1120 in combination with carboplatin and PLD based on number of Dose Limiting Toxicity (DLT) at each dose level
12 months
No
Boehringer Ingelheim
Study Chair
Boehringer Ingelheim Pharmaceuticals
Japan: Ministry of Health, Labor and Welfare
1199.117
NCT01329549
April 2011
October 2012
Name | Location |
---|